Compare Ascendis Pharma A/S (ASND) vs Direxion Daily Semiconductor Bull 3X Shares (SOXL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs Direxion Daily Semiconductor Bull 3X Shares — how do they compare? Ascendis Pharma A/S trades at $270.25 (market cap $17.74B), while Direxion Daily Semiconductor Bull 3X Shares trades at $174.4. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, Direxion Daily Semiconductor Bull 3X Shares nearer its low. Which is the better fit depends on your goals.
| ASND | SOXL | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Leveraged / Inverse |
52-Week High | $277.18 | $300.77 |
52-Week Low | $163.32 | $23.99 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
SOXL trades at $192.26, down 0.1% on the day, with technical indicators signaling a bearish trend as moving averages and ADX point to selling pressure. Recent news highlights extreme volatility, including a 23% single-day drop on June 23, 2026, driven by sector-wide semiconductor sell-offs. The fund faces structural risks from its 3x leverage, which amplifies losses in choppy markets, as noted by Seeking Alpha on July 4, 2026.
The outlook remains high-risk due to leverage decay and semiconductor sector instability. Investment opportunities hinge on a broad AI-driven chip recovery, but risks include volatility decay, hedge fund selling (Goldman Sachs, July 6, 2026), and geopolitical tensions affecting oil markets (New York Post, July 8, 2026).
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Direxion Daily Semiconductor Bull 3X Shares
SOXL is a leveraged ETF that seeks daily investment results corresponding to 300% of the daily performance of the ICE Semiconductor Index. It is designed as a tactical tool for experienced traders to take a bullish (long) position on the semiconductor sector. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on SOXL →
